var data={"title":"Systemic treatment for unresectable malignant pleural mesothelioma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Systemic treatment for unresectable malignant pleural mesothelioma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/contributors\" class=\"contributor contributor_credentials\">Anne S Tsao, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/contributors\" class=\"contributor contributor_credentials\">Nicholas Vogelzang, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/contributors\" class=\"contributor contributor_credentials\">James R Jett, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/contributors\" class=\"contributor contributor_credentials\">Rogerio C Lilenbaum, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/contributors\" class=\"contributor contributor_credentials\">Sadhna R Vora, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, less commonly from the peritoneal surface, and extremely rarely from the tunica vaginalis or pericardium. It often has an extremely poor prognosis; the median survival is 4 to 13 months for untreated patients [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/1\" class=\"abstract_t\">1</a>] and 6 to 18 months for treated patients, regardless of the therapeutic approach [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>The systemic treatment of unresectable malignant pleural mesothelioma (MPM) will be reviewed here, while the application of chemotherapy as a component of a combined-modality approach that includes definitive surgery is discussed separately. (See <a href=\"topic.htm?path=initial-management-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Initial management of malignant pleural mesothelioma&quot;</a>.)</p><p>Other related topics include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=presentation-initial-evaluation-and-prognosis-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Pathology of malignant pleural mesothelioma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1937732754\"><span class=\"h1\">INITIAL EVALUATION AND CLINICAL APPROACH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with malignant pleural mesothelioma (MPM) present with the gradual onset of pulmonary symptoms (dyspnea, cough, chest pain). Symptoms generally lead to a diagnosis when extensive intrathoracic disease is present. (See <a href=\"topic.htm?path=presentation-initial-evaluation-and-prognosis-of-malignant-pleural-mesothelioma#H2\" class=\"medical medical_review\">&quot;Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma&quot;, section on 'Clinical manifestations'</a>.)</p><p class=\"headingAnchor\" id=\"H1937732761\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Typical findings on chest imaging combined with a history of asbestos exposure may raise the suspicion of an MPM. The diagnosis of MPM requires an adequate tissue sample from the tumor. (See <a href=\"topic.htm?path=presentation-initial-evaluation-and-prognosis-of-malignant-pleural-mesothelioma#H6\" class=\"medical medical_review\">&quot;Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Pathology of malignant pleural mesothelioma&quot;</a>.)</p><p>The most widely used staging system is the tumor (T), node (N), metastasis (M) staging system that is used by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) (<a href=\"image.htm?imageKey=ONC%2F111000\" class=\"graphic graphic_table graphicRef111000 \">table 1</a>). (See <a href=\"topic.htm?path=presentation-initial-evaluation-and-prognosis-of-malignant-pleural-mesothelioma#H16615464\" class=\"medical medical_review\">&quot;Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma&quot;, section on 'Staging and pretreatment evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H1937732775\"><span class=\"h2\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A multidisciplinary treatment plan is based upon the assessment of the extent of disease, the patient&rsquo;s overall condition including cardiopulmonary function and other comorbidity, and their desire for aggressive treatment. (See <a href=\"topic.htm?path=initial-management-of-malignant-pleural-mesothelioma#H1741276832\" class=\"medical medical_review\">&quot;Initial management of malignant pleural mesothelioma&quot;, section on 'Patient selection'</a>.):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Surgical candidates</strong> &ndash; For patients who have surgically resectable disease limited to one hemithorax and have no medical contraindication to surgery, we use a combined-modality approach that leads to potential cure. It incorporates surgery aimed at a maximal complete resection (MCR) with chemotherapy and radiation therapy (RT). (See <a href=\"topic.htm?path=initial-management-of-malignant-pleural-mesothelioma#H1852823813\" class=\"medical medical_review\">&quot;Initial management of malignant pleural mesothelioma&quot;, section on 'Surgery-based therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Nonsurgical candidates</strong> &ndash; For patients who have disease in which an MCR is not feasible and for those who are not candidates for definitive surgery because of age, inadequate cardiopulmonary reserve, or other comorbidity, systemic palliative chemotherapy and symptom-directed treatment may be beneficial. (See <a href=\"#H1937732919\" class=\"local\">'Combination chemotherapy'</a> below.)</p><p/><p>After the initial evaluation for possible resection, approximately 80 percent of patients with pleural MPM will not be candidates for combined-modality approach that includes definitive surgery.</p><p class=\"headingAnchor\" id=\"H3402931\"><span class=\"h2\">Response assessment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several ways to assess clinical benefit: response rate, disease control rate, progression-free survival (PFS), and overall survival (OS). OS has been the primary endpoint in contemporary randomized trials [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/4\" class=\"abstract_t\">4</a>]. </p><p>Both the objective response rate and PFS have been used as surrogates for efficacy in older studies [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/5\" class=\"abstract_t\">5</a>]. In malignant pleural mesothelioma studies, there are two radiographic measurement systems that are employed using thoracic computed tomography (CT) scans: Response Evaluation Criteria In Solid Tumors (RECIST) and modified RECIST (<a href=\"image.htm?imageKey=ONC%2F74693\" class=\"graphic graphic_table graphicRef74693 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Modified RECIST measures the pleural rind or tumor thickness in a perpendicular manner to the chest wall in two positions at three separate levels on a chest CT scan [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/8\" class=\"abstract_t\">8</a>]. The sum of these six measurements is used to define response using RECIST criteria.</p><p>Other imaging modalities are under investigation for use in mesothelioma tumor measurements. Positron emission tomography combined with CT scanning <span class=\"nowrap\">(PET/CT)</span> can detect a decrease in metabolic activity in the tumor and may be a better predictor of time to progression rather than objective response as determined by CT alone [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/9\" class=\"abstract_t\">9</a>]. However, the <span class=\"nowrap\">PET/CT</span> endpoint has not been validated in phase III trials.</p><p>Measurement of serum levels of soluble mesothelin-related peptide (SMRP) may be useful in detecting recurrence of disease after surgical resection. However, it is not a US Food and Drug Administration (FDA)-approved assay and does not reliably correlate with response to systemic treatment [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/10\" class=\"abstract_t\">10</a>]. </p><p class=\"headingAnchor\" id=\"H1937732919\"><span class=\"h1\">COMBINATION CHEMOTHERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Combination chemotherapy using the regimen of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> plus <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> became the most widely used regimen, based upon a phase III trial that demonstrated a prolongation of overall survival (OS) compared with treatment with cisplatin alone [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/11\" class=\"abstract_t\">11</a>]. This has been the standard therapy, although the French MAPS trial provides data in support of the addition of <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> to this regimen [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"#H283584673\" class=\"local\">'Pemetrexed cisplatin plus bevacizumab'</a> below.)</p><p class=\"headingAnchor\" id=\"H1937732994\"><span class=\"h2\">Pemetrexed plus cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">Pemetrexed</a> plus <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> is standard treatment for patients with unresectable malignant mesothelioma. After completion of four to six cycles of a platinum-based doublet, it is our general practice to treat with four to six cycles of maintenance pemetrexed (just as in non-small cell lung cancer), although to date, there are no published randomized trials in mesothelioma evaluating maintenance pemetrexed therapy. The addition of <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> to this pemetrexed and cisplatin is discussed elsewhere. (See <a href=\"#H283584673\" class=\"local\">'Pemetrexed cisplatin plus bevacizumab'</a> below.)</p><p>The combination of <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> and <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, incorporating prophylactic <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">folic acid</a> and <a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-drug-information\" class=\"drug drug_general\">vitamin B12</a>, increased OS compared with single-agent cisplatin in patients with malignant pleural mesothelioma (MPM) whose disease was either unresectable or who were not otherwise candidates for potentially curative surgery. In the single-blinded EMPHACIS trial, 456 patients were treated with cisplatin (75 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> and randomly assigned to either pemetrexed (500 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> or placebo, given once every three weeks [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/11\" class=\"abstract_t\">11</a>]. The median survival was significantly longer for the combination (12.1 versus 9.3 months), as was the time to progression (5.7 versus 3.9 months) and the objective response rate (41 versus 17 percent). The EMPHACIS trial did not have a maintenance pemetrexed arm.</p><p>Differences in survival were most striking in patients who received supplementation with <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">folic acid</a> and <a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-drug-information\" class=\"drug drug_general\">vitamin B12</a> during therapy [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/11\" class=\"abstract_t\">11</a>]. Furthermore, treatment-related toxicity was significantly less, and the mean number of administered cycles of therapy (both single-agent <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> as well as the combination) was significantly greater in supplemented compared with non-supplemented patients [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/11,13\" class=\"abstract_t\">11,13</a>].</p><p>In a multivariate regression analysis of prognostic factors derived from this trial, factors predictive of longer OS were therapy group, vitamin supplementation group, Karnofsky performance status (90 to 100 versus 70 to 80, (<a href=\"image.htm?imageKey=PC%2F58785\" class=\"graphic graphic_table graphicRef58785 \">table 3</a>)), disease stage, epithelioid subtype, and white blood cell count <span class=\"nowrap\">(&ge;8200/microL</span> versus lower values) [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/14\" class=\"abstract_t\">14</a>].</p><p>There are no standard assays for predictive biomarkers that are currently recommended. However, a retrospective study of 60 malignant pleural mesothelioma patients correlated low thymidylate synthase levels with improved time to progression and OS [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/15\" class=\"abstract_t\">15</a>]. Prospective trials to evaluate thymidylate synthase as a predictive biomarker for <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> therapy are ongoing.</p><p class=\"headingAnchor\" id=\"H283584673\"><span class=\"h2\">Pemetrexed cisplatin plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The addition of <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> to the pemetrexed-cisplatin regimen improved both progression-free and OS compared with <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> plus <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> without bevacizumab in a large phase III trial. Based on the results of the MAPS study discussed below, cisplatin-pemetrexed-bevacizumab is the accepted standard in France [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/12\" class=\"abstract_t\">12</a>]. The National Comprehensive Cancer Network (NCCN) guidelines have included this regimen as an option for standard front-line therapy, although some insurance companies may not cover it until US Food and Drug Administration (FDA) approval is given. If bevacizumab is being considered, patients should be selected carefully for this treatment. Patients should have no contraindications to bevacizumab therapy (such as poorly controlled hypertension, deep venous thrombosis, proximity to surgery, or viscous perforation) and must have a reasonable performance status. Also, given the poorer prognosis in elderly non-small cell lung cancer (NSCLC) patients with bevacizumab treatment, this agent should be used with caution in patients over the age of 75.</p><p>In the MAPS trial, 448 patients were randomly assigned to pemetrexed-cisplatin plus <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> or to pemetrexed-cisplatin alone. The trial was limited to patients with pleural mesothelioma, and only patients who were not eligible for radical surgery were included. <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> (75 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> and <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> (500 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> were given on day 1 of each of six 21-day cycles. Bevacizumab was given at a dose of 15 <span class=\"nowrap\">mg/kg</span> on day 1, and was continued as maintenance every three weeks following completion of six cycles of chemotherapy. No crossover was allowed.</p><p>Results were as follows [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/12\" class=\"abstract_t\">12</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With a median follow-up of 39 months, PFS was significantly increased with the <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> combination compared with cisplatin-pemetrexed alone (median, 9.2 versus 7.3 months; hazard ratio [HR] 0.61, 95% CI 0.50-0.75).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>OS was significantly increased with the combination as well (median, 18.8 versus 16.1 months; HR 0.77, 95% CI 0.62-0.95).</p><p/><p>The improvement in OS was in contrast to three prior phase II trials. This may have been partially attributable to limiting the pemetrexed-cisplatin to six cycles, rather than continuing with maintenance. </p><p class=\"headingAnchor\" id=\"H1937733683\"><span class=\"h2\">Pemetrexed plus carboplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">Carboplatin</a> has been substituted for <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> in conjunction with <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> in an effort to decrease toxicity [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/16-18\" class=\"abstract_t\">16-18</a>].</p><p>In the larger of two non-randomized phase II studies, 102 patients were treated every 21 days with <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> (area under the curve [AUC] 5) plus <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> (500 <span class=\"nowrap\">mg/m<sup>2</sup>),</span> with <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">folic acid</a> and <a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-drug-information\" class=\"drug drug_general\">vitamin B12</a> supplementation [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/16\" class=\"abstract_t\">16</a>]. Objective responses were observed in 19 percent, with a median time to progression of 6.5 months and a median survival of 12.7 months. A secondary analysis of two of these trials based upon patient age found that the carboplatin plus pemetrexed regimen was well tolerated and had a similar level of activity in those &ge;70 years, compared with those who were younger [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/19\" class=\"abstract_t\">19</a>].</p><p>These results are similar to those with the cisplatin-based combination, and <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> plus <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> may be an alternative regimen if <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> toxicity is a particular concern. There are no data from large studies on the addition of <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> to the pemetrexed-carboplatin regimen.</p><p class=\"headingAnchor\" id=\"H1937733690\"><span class=\"h2\">Raltitrexed plus cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of <a href=\"topic.htm?path=raltitrexed-united-states-not-available-drug-information\" class=\"drug drug_general\">raltitrexed</a> plus <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> prolongs survival compared with cisplatin alone in patients with previously untreated advanced mesothelioma.</p><p>This was illustrated in a phase III trial in which 250 patients were randomly assigned to <a href=\"topic.htm?path=raltitrexed-united-states-not-available-drug-information\" class=\"drug drug_general\">raltitrexed</a> (3 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> plus <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> (80 <span class=\"nowrap\">mg/m<sup>2</sup>,</span> both in 21-day cycles) or the same dose of cisplatin alone [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/20,21\" class=\"abstract_t\">20,21</a>]. The following findings were noted:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>OS in all randomized patients was significantly increased with the combination regimen: the median survival was 11.4 versus 8.8 months with single-agent <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, and the one-year survival was 46 versus 40 percent [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the 213 patients with measurable disease, the combined therapy group had a higher objective response rate (24 versus 14 percent, p = 0.06) [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A separate analysis of health-related quality of life (QOL) showed that overall QOL was impaired at baseline but was stable for those remaining on treatment with both regimens [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/21\" class=\"abstract_t\">21</a>]. Dyspnea improved with treatment, an effect that was statistically significant for the two-drug regimen.</p><p/><p><a href=\"topic.htm?path=raltitrexed-united-states-not-available-drug-information\" class=\"drug drug_general\">Raltitrexed</a> is not commercially available in the United States.</p><p class=\"headingAnchor\" id=\"H3402373\"><span class=\"h2\">Gemcitabine plus cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">Gemcitabine</a> has been combined with platinum compounds, including <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/22-26\" class=\"abstract_t\">22-26</a>], <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/27\" class=\"abstract_t\">27</a>], and <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/28\" class=\"abstract_t\">28</a>]. Response rates for these combinations have ranged from 15 to 48 percent, with acceptable levels of toxicity. However, it is generally accepted that mesothelioma patients should receive pemetrexed-based therapy in the first-line setting.</p><p><a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">Gemcitabine</a> plus <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> regimen was evaluated in a multicenter phase II trial, in which 106 previously untreated patients were treated with gemcitabine plus cisplatin and randomly assigned to receive either <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> or placebo [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/26\" class=\"abstract_t\">26</a>]. The median survival was approximately 15 months on both treatment arms, consistent with the results seen with cisplatin plus <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/4\" class=\"abstract_t\">4</a>]. No OS benefit was observed with the addition of bevacizumab in this regimen; however, a potential benefit may have been obscured by the use of pemetrexed as second-line therapy.</p><p class=\"headingAnchor\" id=\"H3402445\"><span class=\"h2\">Other regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> has also been combined with a number of older chemotherapy agents in phase II studies. These include anthracyclines (<a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, <a href=\"topic.htm?path=epirubicin-drug-information\" class=\"drug drug_general\">epirubicin</a>) [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/29-32\" class=\"abstract_t\">29-32</a>]; the combination of <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a>, <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a>, plus <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/29-31\" class=\"abstract_t\">29-31</a>]; and the combination of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> plus <a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">vinblastine</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/33,34\" class=\"abstract_t\">33,34</a>].</p><p>The results from these studies do not suggest any advantage compared with combinations of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> plus either <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> or <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> and in fact may be somewhat inferior [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/34,35\" class=\"abstract_t\">34,35</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">SECOND-LINE TREATMENT WITH SINGLE-AGENT CHEMOTHERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While it is recommended that a platinum-pemetrexed-based regimen be used in the first-line setting, there are no US Food and Drug Administration (FDA)-approved therapies for salvage treatment of mesothelioma. In general, single-agent monotherapy is an accepted practice, and phase II studies have found that a number of agents lead to improved response rates. However, if patients developed disease progression in the setting of a prolonged treatment break from a platinum-pemetrexed-based regimen, they can be rechallenged with the platinum-pemetrexed-based regimen before attempting further lines of single-agent therapy. (See <a href=\"#H1937732994\" class=\"local\">'Pemetrexed plus cisplatin'</a> above.)</p><p>Although single-agent chemotherapy has not been shown to prolong survival in previously untreated patients [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/4\" class=\"abstract_t\">4</a>], an analysis of the phase III EMPHACIS trial identified second-line (post-study) chemotherapy as a significant predictor of extended survival [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/11,36\" class=\"abstract_t\">11,36</a>]. First-line therapy and further results of this study are discussed elsewhere. (See <a href=\"#H1937732994\" class=\"local\">'Pemetrexed plus cisplatin'</a> above.)</p><p>Agents that have shown substantial activity as single agents in phase II trials include the following:</p><p class=\"headingAnchor\" id=\"H3402035\"><span class=\"h2\">Pemetrexed</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most extensive data in the second-line setting are for <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a>, either alone or in combination with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/36-41\" class=\"abstract_t\">36-41</a>]. Other drugs that have been used include <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>, <a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">vinorelbine</a>, and anthracyclines. (See <a href=\"#H3402298\" class=\"local\">'Other agents'</a> below.)</p><p>In a study of 243 previously treated patients randomly assigned to <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> or best supportive care, pemetrexed significantly increased the median progression-free survival (PFS), time to progression, and time to treatment failure (3.6 versus 1.5, 3.7 versus 1.5, and 3.6 versus 1.5 months, respectively) [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/41\" class=\"abstract_t\">41</a>].</p><p>However, <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> did not improve median survival (8.4 versus 9.7 months with best supportive care). An overall survival (OS) benefit may have been obscured, since 52 percent of those assigned to best supportive care received systemic chemotherapy once disease progression was evident. </p><p class=\"headingAnchor\" id=\"H3402298\"><span class=\"h2\">Other agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several other agents have also demonstrated activity in phase II studies, based upon rates of objective tumor regression. These may be useful as second-line therapy when they were not part of the original chemotherapy regimen. Such agents include <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/42-44\" class=\"abstract_t\">42-44</a>], anthracyclines [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/45-47\" class=\"abstract_t\">45-47</a>], and vinca alkaloids [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/44,48,49\" class=\"abstract_t\">44,48,49</a>]. The use of single-agent <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> is discussed above (see <a href=\"#H3402035\" class=\"local\">'Pemetrexed'</a> above). Other antifolates with single-agent activity include <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/50\" class=\"abstract_t\">50</a>], edatrexate [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/51\" class=\"abstract_t\">51</a>], and <a href=\"topic.htm?path=raltitrexed-united-states-not-available-drug-information\" class=\"drug drug_general\">raltitrexed</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">EXPERIMENTAL APPROACHES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A range of other approaches have been or are being studied in an effort to improve upon the systemic therapy for pleural mesothelioma. None of these has an established role in the treatment of mesothelioma and is not indicated outside the context of a formal clinical trial.</p><p class=\"headingAnchor\" id=\"H2153630705\"><span class=\"h2\">Pemetrexed, cisplatin, plus nintedanib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Combination chemotherapy with <a href=\"topic.htm?path=nintedanib-drug-information\" class=\"drug drug_general\">nintedanib</a>, a VEGFR, PDGFR, and FGFR tyrosine kinase inhibitor, has shown efficacy. The LUME-Meso phase II trial randomly assigned 87 chemo-na&iuml;ve MPM patients receiving <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> and <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> to also receive placebo or nintedanib [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/53\" class=\"abstract_t\">53</a>]. The nintedanib arm had a superior progression-free survival (PFS, 9.4 versus 5.7 months; hazard ratio [HR] 0.54, 95% CI 0.33&ndash;0.87) and overall survival (OS, 18.3 versus 14.2 months; HR 0.77, 95% CI 0.46&ndash;1.29). Patients with epithelioid histology, typically a favorable prognostic feature, had the highest PFS benefit with nintedanib (HR 0.49, 95% CI 0.30&ndash;0.82). The international phase III LUME-Meso trial is underway and will only enroll MPM patients with epithelioid histology (NCT01907100).</p><p class=\"headingAnchor\" id=\"H136074073\"><span class=\"h2\">Immunotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunotherapy using checkpoint inhibitors may offer a more promising direction for disease control [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/54,55\" class=\"abstract_t\">54,55</a>]. For example, in one study, treatment of 25 mesothelioma patients (88 percent with previous systemic therapy) with the anti-programmed cell death 1 (PD-1) antibody <a href=\"topic.htm?path=pembrolizumab-drug-information\" class=\"drug drug_general\">pembrolizumab</a> resulted in 5 partial responses and 13 patients with stable disease, for an overall disease control rate of 72 percent [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/55\" class=\"abstract_t\">55</a>]. All responding patients remained on therapy at the time of analysis. Additional clinical studies with pembrolizumab are being initiated. Preliminary results of a randomized phase II trial of second- or third-line <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">nivolumab</a>, with or without <a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">ipilimumab</a>, suggest objective response rates of 24 and 18 percent and disease control rates of 52 and 40 percent, respectively, in an intention-to-treat population. More study is required before routine clinical use [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/54\" class=\"abstract_t\">54</a>]. </p><p>Other immunotherapies, such as the CTLA-4 inhibitor tremelimumab, were studied in a randomized phase II trial of 571 patients (DETERMINE), but unfortunately showed no survival benefit beyond placebo (7.7 versus 7.3 months, respectively; HR 0.92, 95% CI 0&middot;76-1&middot;12) [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/56\" class=\"abstract_t\">56</a>].</p><p>Older immunotherapeutic approaches using interferons or interleukin-2, either alone or in combination with chemotherapy, did not offer substantive advantage [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/57-60\" class=\"abstract_t\">57-60</a>].</p><p class=\"headingAnchor\" id=\"H2371252055\"><span class=\"h2\">Other agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vorinostat-drug-information\" class=\"drug drug_general\">Vorinostat</a>, an oral histone deacetylase inhibitor, showed some evidence of activity in an initial phase I study [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/61\" class=\"abstract_t\">61</a>]. However, more extensive evaluation did not confirm a clinically meaningful benefit from this approach. In a phase III trial, 661 previously treated patients were randomly assigned to either vorinostat or placebo [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/62\" class=\"abstract_t\">62</a>]. PFS was prolonged with vorinostat (median, 6.3 versus 6.1 weeks; HR 0.75, 95% CI 0.63-0.88). However, this increase was not clinically significant. Also, the difference in OS was not significant (median, 30.7 versus 27.1 weeks; HR 0.98, 95% CI 0.83-1.17).</p><p>Agents targeting mesothelin, such as MORAb-009, SS1P, BAY 9409343, and CRS-207, have showed preliminary efficacy against mesothelioma in clinical trials. Several randomized trials are ongoing.</p><p>Other experimental agents that have been studied include angiogenesis inhibitors (<a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/63\" class=\"abstract_t\">63</a>]) and tyrosine kinase inhibitors (<a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/64\" class=\"abstract_t\">64</a>], <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/64\" class=\"abstract_t\">64</a>], <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/65-67\" class=\"abstract_t\">65-67</a>], vatalanib [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/68\" class=\"abstract_t\">68</a>], and cediranib [<a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/69\" class=\"abstract_t\">69</a>]).</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=pleural-mesothelioma-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Pleural mesothelioma (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with advanced pleural mesotheliomas (MPM) who are not candidates for a combined-modality approach that incorporates definitive surgery, we recommend treatment with combination chemotherapy using a platinum-based doublet rather than single-agent chemotherapy (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). This approach has been shown to significantly prolong overall survival compared with single-agent chemotherapy using <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>. (See <a href=\"#H1937732919\" class=\"local\">'Combination chemotherapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Our general approach is to utilize a platinum agent with <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a>, also including prophylactic <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">folic acid</a> and <a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-drug-information\" class=\"drug drug_general\">vitamin B12</a>. </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>An acceptable alternative strategy is the addition of <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> to <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> and <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a>, which has been shown to increase progression-free and overall survival. At this time, regulatory approval is pending for bevacizumab with cisplatin and pemetrexed. Patients should be appropriately selected to receive this regimen, generally being younger than 75 years of age with a good performance status and without contraindications to bevacizumab. (See <a href=\"#H283584673\" class=\"local\">'Pemetrexed cisplatin plus bevacizumab'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We also administer maintenance <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> after four to six cycles of the platinum-pemetrexed doublet. (See <a href=\"#H1937732994\" class=\"local\">'Pemetrexed plus cisplatin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who progress on their initial platinum-based regimen, we suggest single-agent chemotherapy with an active agent such as <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> or <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> that was not included in the original chemotherapy regimen if disease progression occurred within three to four months of stopping therapy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). If patients have had disease indolence over six months since their original therapy, they can be rechallenged with the same regimen. Other older agents that also have some activity in MPM include anthracyclines and vinca alkaloids.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The chemotherapy approaches used in the treatment of advanced MPM have been integrated into combined-modality approaches along with definitive surgery and radiation therapy. These approaches are discussed separately. (See <a href=\"topic.htm?path=initial-management-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Initial management of malignant pleural mesothelioma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients should be encouraged to participate in formal clinical trials whenever possible.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/1\" class=\"nounderline abstract_t\">Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14:1007.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/2\" class=\"nounderline abstract_t\">Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/3\" class=\"nounderline abstract_t\">Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107:332S.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/4\" class=\"nounderline abstract_t\">Vogelzang NJ. Chemotherapy for malignant pleural mesothelioma. Lancet 2008; 371:1640.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/5\" class=\"nounderline abstract_t\">Francart J, Legrand C, Sylvester R, et al. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. J Clin Oncol 2006; 24:3007.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/6\" class=\"nounderline abstract_t\">Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/7\" class=\"nounderline abstract_t\">Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/8\" class=\"nounderline abstract_t\">Nowak AK. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 2005; 49 Suppl 1:S37.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/9\" class=\"nounderline abstract_t\">Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006; 24:4587.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/10\" class=\"nounderline abstract_t\">Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010; 28:3316.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/11\" class=\"nounderline abstract_t\">Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/12\" class=\"nounderline abstract_t\">Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387:1405.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/13\" class=\"nounderline abstract_t\">Vogelzang NJ, Emri S, Boyer MJ, et al. Effect of folic acid and vitamin B12 supplmentation on risk-benefit ratio from phase III study of pemetrexed and cisplatin versus cisplatin in malignan pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 2003; 22:657a.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/14\" class=\"nounderline abstract_t\">Symanowski JT, Rusthoven J, Nguyen B, et al. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 2003; 22:647a.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/15\" class=\"nounderline abstract_t\">Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010; 28:1534.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/16\" class=\"nounderline abstract_t\">Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/17\" class=\"nounderline abstract_t\">Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/18\" class=\"nounderline abstract_t\">Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona&iuml;ve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/19\" class=\"nounderline abstract_t\">Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008; 99:51.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/20\" class=\"nounderline abstract_t\">van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/21\" class=\"nounderline abstract_t\">Bottomley A, Gaafar R, Manegold C, et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 2006; 24:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/22\" class=\"nounderline abstract_t\">Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87:491.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/23\" class=\"nounderline abstract_t\">Castagneto B, Zai S, Dongiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005; 28:223.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/24\" class=\"nounderline abstract_t\">J&auml;nne PA, Simon GR, Langer CJ, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol 2008; 26:1465.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/25\" class=\"nounderline abstract_t\">Kovac V, Zwitter M, Rajer M, et al. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 2012; 23:230.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/26\" class=\"nounderline abstract_t\">Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30:2509.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/27\" class=\"nounderline abstract_t\">Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97:2791.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/28\" class=\"nounderline abstract_t\">Schutte W, Blankenburg T, Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003; 4:294.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/29\" class=\"nounderline abstract_t\">Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/30\" class=\"nounderline abstract_t\">Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991; 67:2984.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/31\" class=\"nounderline abstract_t\">Henss H, Fiebig HH, Schildge J, et al. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 1988; 11:118.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/32\" class=\"nounderline abstract_t\">Berghmans T, Lafitte JJ, Paesmans M, et al. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 2005; 50:75.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/33\" class=\"nounderline abstract_t\">Hunt KJ, Longton G, Williams MA, Livingston RB. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996; 109:1239.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/34\" class=\"nounderline abstract_t\">Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9:269.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/35\" class=\"nounderline abstract_t\">Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371:1685.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/36\" class=\"nounderline abstract_t\">Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005; 16:923.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/37\" class=\"nounderline abstract_t\">Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/38\" class=\"nounderline abstract_t\">Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17:1194.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/39\" class=\"nounderline abstract_t\">Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemona&iuml;ve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008; 3:764.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/40\" class=\"nounderline abstract_t\">J&auml;nne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006; 1:506.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/41\" class=\"nounderline abstract_t\">Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26:1698.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/42\" class=\"nounderline abstract_t\">van Meerbeeck JP, Baas P, Debruyne C, et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999; 85:2577.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/43\" class=\"nounderline abstract_t\">Kindler HL, Millard F, Herndon JE 2nd, et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001; 31:311.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/44\" class=\"nounderline abstract_t\">Toyokawa G, Takenoyama M, Hirai F, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2014; 19:601.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/45\" class=\"nounderline abstract_t\">Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52:1981.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/46\" class=\"nounderline abstract_t\">Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee. Tumori 1991; 77:49.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/47\" class=\"nounderline abstract_t\">Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest 2002; 20:693.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/48\" class=\"nounderline abstract_t\">Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/49\" class=\"nounderline abstract_t\">Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007; 25:4751.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/50\" class=\"nounderline abstract_t\">Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65:956.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/51\" class=\"nounderline abstract_t\">Kindler HL, Belani CP, Herndon JE 2nd, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 1999; 86:1985.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/52\" class=\"nounderline abstract_t\">Baas P, Ardizzoni A, Grossi F, et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003; 39:353.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/53\" class=\"nounderline abstract_t\">Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. J Clin Oncol 2017; 35:3591.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/54\" class=\"nounderline abstract_t\">Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol 2017; 35S:LBA8507.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/55\" class=\"nounderline abstract_t\">Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017; 18:623.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/56\" class=\"nounderline abstract_t\">Maio M, Scherpereel A, Calabr&ograve; L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 2017; 18:1261.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/57\" class=\"nounderline abstract_t\">Parra HS, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001; 92:650.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/58\" class=\"nounderline abstract_t\">Halme M, Knuuttila A, Vehmas T, et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999; 80:1781.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/59\" class=\"nounderline abstract_t\">Bretti S, Berruti A, Dogliotti L, et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 1998; 84:558.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/60\" class=\"nounderline abstract_t\">Calabr&ograve; L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013; 14:1104.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/61\" class=\"nounderline abstract_t\">Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/62\" class=\"nounderline abstract_t\">Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2015; 16:447.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/63\" class=\"nounderline abstract_t\">Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 2013; 14:543.</a></li><li class=\"breakAll\">Nowak AK, Millward MJ, Francis J, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 2008; 15s:8063. (Abstract available online at http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8063, accessed April 26, 2010).</li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/65\" class=\"nounderline abstract_t\">Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50:83.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/66\" class=\"nounderline abstract_t\">Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007; 59:149.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/67\" class=\"nounderline abstract_t\">Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma (abstract 912). Proc Am Soc Clin Oncol 2003; 22:912.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/68\" class=\"nounderline abstract_t\">Jahan PA, Wang XF, Krug ML, et al. Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307) (abstract 7707). J Clin Oncol 2007; 25:18s.</a></li><li><a href=\"https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma/abstract/69\" class=\"nounderline abstract_t\">Van Schil PE, Baas P, Gaafar R, et al. Phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy for cT3N1M0 or less malignant pleural mesothelioma (EORTC 08031) (abstract 7509). J Clin Oncol 2008; 27:384s.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4609 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H20\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1937732754\" id=\"outline-link-H1937732754\">INITIAL EVALUATION AND CLINICAL APPROACH</a><ul><li><a href=\"#H1937732761\" id=\"outline-link-H1937732761\">Diagnosis</a></li><li><a href=\"#H1937732775\" id=\"outline-link-H1937732775\">Clinical approach</a></li><li><a href=\"#H3402931\" id=\"outline-link-H3402931\">Response assessment</a></li></ul></li><li><a href=\"#H1937732919\" id=\"outline-link-H1937732919\">COMBINATION CHEMOTHERAPY</a><ul><li><a href=\"#H1937732994\" id=\"outline-link-H1937732994\">Pemetrexed plus cisplatin</a></li><li><a href=\"#H283584673\" id=\"outline-link-H283584673\">Pemetrexed cisplatin plus bevacizumab</a></li><li><a href=\"#H1937733683\" id=\"outline-link-H1937733683\">Pemetrexed plus carboplatin</a></li><li><a href=\"#H1937733690\" id=\"outline-link-H1937733690\">Raltitrexed plus cisplatin</a></li><li><a href=\"#H3402373\" id=\"outline-link-H3402373\">Gemcitabine plus cisplatin</a></li><li><a href=\"#H3402445\" id=\"outline-link-H3402445\">Other regimens</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">SECOND-LINE TREATMENT WITH SINGLE-AGENT CHEMOTHERAPY</a><ul><li><a href=\"#H3402035\" id=\"outline-link-H3402035\">Pemetrexed</a></li><li><a href=\"#H3402298\" id=\"outline-link-H3402298\">Other agents</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">EXPERIMENTAL APPROACHES</a><ul><li><a href=\"#H2153630705\" id=\"outline-link-H2153630705\">Pemetrexed, cisplatin, plus nintedanib</a></li><li><a href=\"#H136074073\" id=\"outline-link-H136074073\">Immunotherapy</a></li><li><a href=\"#H2371252055\" id=\"outline-link-H2371252055\">Other agents</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H32892193\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/4609|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/111000\" class=\"graphic graphic_table\">- Malignant pleural mesothelioma TNM staging AJCC 2017</a></li><li><a href=\"image.htm?imageKey=ONC/74693\" class=\"graphic graphic_table\">- RECIST response criteria solid tumors</a></li><li><a href=\"image.htm?imageKey=PC/58785\" class=\"graphic graphic_table\">- Karnofsky Performance Status scale</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Epidemiology of malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-management-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Initial management of malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Pathology of malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pleural-mesothelioma-the-basics\" class=\"medical medical_basics\">Patient education: Pleural mesothelioma (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=presentation-initial-evaluation-and-prognosis-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma</a></li></ul></div></div>","javascript":null}